ASP3026 is A potent and selective ALK ( Anaplastic Lymphoma Kinase) inhibitor. It is more selective than Crizotinib in a kinase panel, and showed potent anti-tumor activity in an EML4-ALK driven tumor model with gatekeeper mutation while Crizotinib was ineffective even at 100 mg/gk qd . It is currently in clinical trials. [1]